<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">100962779</journal-id>
<journal-id journal-id-type="pubmed-jr-id">22269</journal-id>
<journal-id journal-id-type="nlm-ta">Nat Rev Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Nat. Rev. Genet.</journal-id>
<journal-title-group>
<journal-title>Nature reviews. Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1471-0056</issn>
<issn pub-type="epub">1471-0064</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30737492</article-id>
<article-id pub-id-type="pmc">6584039</article-id>
<article-id pub-id-type="doi">10.1038/s41576-019-0100-z</article-id>
<article-id pub-id-type="manuscript">NIHMS1017230</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Induced pluripotent stem cells in disease modelling and drug discovery</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Rowe</surname>
<given-names>R. Grant</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Daley</surname>
<given-names>George Q.</given-names>
</name>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<aff id="A1">Boston Children’s Hospital and Harvard Medical School, Boston, MA, USA</aff>
</contrib-group>
<author-notes>
<corresp id="CR1">
<label>*</label>
<email>george_daley@hms.harvard.edu</email>
</corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P39">Competing interests</p>
<p id="P40">G. Q. D. holds intellectual property relevant to development of cell and drug therapies based on IPSC technology.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>14</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>7</month>
<year>2020</year>
</pub-date>
<volume>20</volume>
<issue>7</issue>
<fpage>377</fpage>
<lpage>388</lpage>
<!--elocation-id from pubmed: 10.1038/s41576-019-0100-z-->
<abstract id="ABS1">
<p id="P1">The derivation of induced pluripotent stem cells (iPSCs) over a decade ago sparked widespread enthusiasm for the
development of new models of human disease, enhanced platforms for drug discovery, and more widespread use of autologous
cell-based therapy. Early studies using directed differentiation of iPSCs frequently uncovered cell-level phenotypes in monogenic
diseases, but translation to tissue-level and organ-level diseases has required development of more complex, 3D, multicellular
systems. Organoids and human–rodent chimaeras more accurately mirror the diverse cellular ecosystems of complex tissues and
are being applied to iPSC disease models to recapitulate the pathobiology of a broad spectrum of human maladies, including
infectious diseases, genetic disorders and cancer.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>